| Literature DB >> 31190774 |
Zyta Beata Wojszel1,2, Agnieszka Kasiukiewicz1,2, Marta Swietek2,3, Michal Lukasz Swietek3, Lukasz Magnuszewski2,3.
Abstract
Purpose: Atrial fibrillation (AF) is an increasingly common rhythm disorder and an important risk factor of ischemic stroke, heart failure, hospitalization, and cardiovascular mortality. Its diagnosis, however, is often delayed because of silent character of the arrhythmia. The aim of the study was to identify independent determinants of AF in patients of the geriatric ward, so as to be able to propose a strategy for screening of this arrhythmia.Entities:
Keywords: CHA2DS2-VASc score; atrial fibrillation screening; older people; risk factors and determinants
Mesh:
Year: 2019 PMID: 31190774 PMCID: PMC6527793 DOI: 10.2147/CIA.S206976
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Characteristics of the study groups - with AF (AF+ group) and without AF (AF- group)
| Parameter | Total | AF+ group | AF- group | Missing data | |
|---|---|---|---|---|---|
| No. (%) of patients | 416 (100.0) | 98 (23.6) | 318 (76.4) | ||
| Age, y, Me (IQR) | 82 (77–86) | 84 (84.0–87.0) | 82 (76–86) | 0.002 | - |
| Gender, men, n (%) | 94 (22.09) | 31 (31.6) | 63 (19.8) | 0.01 | - |
| Place of residence, rural, n (%) | 87 (20.9) | 21 (21.4) | 66 (20.8) | 0.89 | - |
| Education, elementary or less, n (%) | 231 (66.2) | 54 (65.9) | 177 (65.3) | 0.92 | 65 |
| Living alone, n (%) | 119 (29,8) | 19 (20,4) | 100 (32,7) | 0,02 | 17 |
| Unable to walk outside the house without help, n (%) | 150 (37,5) | 34 (35,1) | 116 (38,3) | 0,56 | 16 |
| Barthel Index, Me (IQR) | 90 (70–100) | 90 (65–97.5) | 90 (70–100) | 0.26 | 6 |
| I-ADL, Me (IQR) | 7 (3–11) | 7 (3–9.25) | 8 (3–11) | 0.09 | 10 |
| Number of chronic diseases, Me (IQR) | 4 (3–6) | 6 (5–7) | 4 (3–5) | <0.001 | - |
| Multimorbidity, n (%) | 201 (48.3) | 86 (87.8) | 153 (48.1) | <0.001 | - |
| Number of drugs, Me (IQR) | 7 (5–9) | 8 (6–10) | 7 (5–9) | 0.001 | 9 |
| Polypharmacy, n (%) | 322 (79.1) | 86 (89.6) | 236 (75.9) | 0.004 | 9 |
| Inactivity, n (%) | 168 (41.0) | 51 (52.0) | 117 (37.5) | 0.01 | 8 |
| Hospitalization in the last 12 months, n (%) | 122 (29.5) | 37 (38.1) | 85 (26.9) | 0.03 | 3 |
| BMI, kg/m2, M (SD) | 29.25 (5.98) | 30,19 (5.53) | 28,98 (6.08) | 0.114 | 62 |
| Medications | |||||
| ß-blockers, n (%) | 258 (63.5) | 79 (82.3) | 179 (57.7) | <0.001 | 10 |
| ACE-Is/ARBs, n (%) | 259 (63.8) | 67 (69.8) | 192 (61.9) | 0.16 | 10 |
| Calcium channel blockers, n (%) | 114 (28.1) | 22 (22.9) | 92 (29.7) | 0.20 | 10 |
| α1-blockers, n (%) | 25 (6.2) | 10 (10.4) | 15 (4.8) | 0.05 | 10 |
| Antiarrhythmic, n (%) | 9 (2.2) | 6 (6.3) | 3 (1.0) | 0.002 | 10 |
| Digoxin, n (%) | 30 (7.4) | 26 (27.1) | 4 (1.3) | <0.001 | 10 |
| Thiazide, n (%) | 83 (20.4) | 13 (13.5) | 70 (22.6) | 0.06 | 10 |
| Loop diuretics, n (%) | 100 (24.6) | 47 (49.0) | 53 (17.1) | <0.001 | 10 |
| Aldosterone- receptor antagonists, n (%) | 71 (17.5) | 32 (33.3) | 39 (12.6) | <0.001 | 10 |
| Statins, n (%) | 142 (35.0) | 29 (30.2) | 113 (36.5) | 0.26 | 10 |
| Antiplatelet, n (%) | 128 (31.5) | 25 (26.0) | 103 (33.2) | 0.19 | 10 |
| Anticoagulants, n (%) | 64 (15.4) | 57 (58.2) | 7 (2.2) | <0.001 | 10 |
| Hemoglobin, mmol/L, M (SD) | 7.76 (1.09) | 7.64 (1.17) | 7.80 (1.06) | 0.19 | 12 |
| Anemia, n (%) | 177 (43.8) | 54 (56.3) | 123 (39.9) | 0.005 | 12 |
| GFR, l/min/1.73m2, M (SD) | 218 (52.4) | 51.72 (17.73) | 60.11 (16.31) | <0.001 | 11 |
| Serum creatinine, mmol/L, Me (IQR) | 86.63 (74.26–105.20) | 99.01 (79.34–119.56) | 84.86 (72.49–98.12) | <0.001 | 11 |
| HAS-BLED, Me (IQR) | 2 (1–2) | 2 (2–3) | 1 (1–2) | <0.001 | 2 |
| HAS-BLED≥3, n (%) | 63 (15.2) | 37 (38.1) | 26 (8.2) | <0.001 | 2 |
| CHADS2-VASC, Me (IQR) | 4 (3–5) | 5 (4–6) | 3 (3–4.5) | <0.001 | 2 |
Notes: aχ2 test or Fisher exact test, as appropriate, for categorical variables. Student's t-test or Mann–Whitney test for continuous or interval variables.
Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; ARBs, angiotensin II receptor blockers; BMI, body mass index; GFR, glomerular filtration rate; IADL, instrumental activities of daily living; IQR, interquartile range; M, mean value; Me, median value; n, number of cases.
Clinical correlates and risk factors of AF in the study group
| Parameter | Total | AF+ group | AF- group | RR (95% CI) | |
|---|---|---|---|---|---|
| No. (%) of patients | 416 (100.0) | 98 (23.6) | 318 (76.4) | ||
| Age, 75+, n (%) | 350 (84.1) | 93 (94.9) | 257 (80.8) | 3.51 (1.5–8.3) | 0.001 |
| Gender, men, n (%) | 94 (22.09) | 31 (31.6) | 63 (19.8) | 1.59 (1.1–2.3) | 0.01 |
| Coronary artery disease, n (%) | 223 (53.6) | 58 (59.2) | 165 (51.9) | 1.26 (0.9–1.8) | 0.21 |
| Myocardial infarction, n (%) | 39 (9.4) | 14 (14.3) | 25 (7.9) | 1.61 (1.0–2.6) | 0.06 |
| Hypertension, n (%) | 327 (78.6) | 80 (81.6) | 247 (77.7) | 1.21 (0.8–1.9) | 0.40 |
| Peripheral arterial disease, n (%) | 64 (15.4) | 27 (27.6) | 37 (11.6) | 2.09 (1.5–3.0) | <0.001 |
| CHF, n (%) | 162 (38.9) | 71 (72.4) | 91 (28.6) | 4.12 (2.8–6.1) | <0.001 |
| Stroke and TIA, n (%) | 56 (13.5) | 22 (22.4) | 34 (10.7) | 1.86 (1.3–2.7) | 0.003 |
| Diabetes, n (%) | 126 (30.3) | 38 (38.8) | 88 (27.7) | 1.46 (1.0–2.1) | 0.04 |
| COPD, n (%) | 42 (10,1) | 13 (13,3) | 29 (9,1) | 1.4 (0.8–2.2) | 0,23 |
| Thyroid dysfunction, n (%) | 74 (17,8) | 17 (17,4) | 57 (17,9) | 0.97 (0.6–1.5) | 0,89 |
| Chronic kidney disease, n (%) | 218 (52.4) | 64 (65.3) | 154 (48.4) | 1,71 (1.2–2.5) | 0.003 |
| BMI≥30 kg/m2, n (%) | 148 (41.8) | 36 (45.6) | 112 (40.7) | 1.17 (0.8–1.7) | 0.44 |
| Smoking, n (%) | 35 (8.8) | 10 (10.8) | 25 (8.2) | 1.25 (0.7–2.2) | 0.45 |
| Alcohol drinking, n (%) | 7 (1.8) | 3 (3.2) | 4 (1.4) | 1.82 (0.8–4.4) | 0.24 |
| Inactivityd, n (%) | 168 (41.0) | 51 (52.0) | 117 (37.5) | 1.56 (1.1–2.2) | 0.01 |
Note: aχ2 test.
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; n, number of cases; RR, relative risk; TIA, transient ischemic attack.
Risk factors associated with AF - multivariable logistic regression model
| OR | 95% CI | ||
|---|---|---|---|
| Congestive heart failure | 5.43 | 3.14–9.39 | <0.001 |
| Age, 75+ years | 4.00 | 1.43–11.20 | 0.008 |
| Stroke and TIA | 2.10 | 1.06–4.13 | 0.03 |
| Gender, men | 1.50 | 0.82–2.73 | 0.19 |
| Peripheral arterial disease | 1.50 | 0.76–2.95 | 0.24 |
| Diabetes | 1.38 | 0.80–2.37 | 0.25 |
| Myocardial infarction | 0.68 | 0.31–1.52 | 0.35 |
| Chronic kidney disease | 1.17 | 0.68–2.02 | 0.58 |
Abbreviations: CI, confidence interval; OR, odds ratio; TIA, transient ischemic attack.
Figure 1Receiver operating characteristics (ROC) curve analysis for the ability of age 75 or above (AGE_75plus), history of stroke (STROKE), heart failure (HF), and CHA2DS2-VASC score (CHA2DS2_VASC) to predict atrial fibrillation (AF).
The values of CHA2DS2-VASC score, CHF diagnosis, history of stroke/TIA, and age 75years or above for the prediction of AF and their overall diagnostic effectiveness
| ROC Index | CHA2DS2-VASC score | CHF | Age, 75+years | Stroke-TIA |
|---|---|---|---|---|
| AUC | 0.75 | 0.72 | 0.57 | 0.56 |
| 95% CI of AUC | 0.70–0.80 | 0.66–0.78 | 0.51–0.63 | 0.49–0.63 |
| <0.001 | <0.001 | 0.02 | 0.09 | |
| Youden Index J | 0.391 | 0.438 | 0.141 | 0.118 |
| Cut-off criterion | 4 | 1* | 1* | 1* |
| Sensitivity (%) | 0.89 | 0.72 | 0.95 | 0.22 |
| 95% CI of sensitivity | 0.81–0.94 | 0.63–0.81 | 0.89–0.98 | 0.15–0.32 |
| Specificity | 0.51 | 0.71 | 0.19 | 0.89 |
| 95% CI of specificity | 0.45–0.56 | 0.66–0.76 | 0.15–0.24 | 0.85–0.93 |
| Positive likelihood ratio | 1.79 | 2.53 | 2.1 | 1.17 |
| Negative likelihood ratio | 0.23 | 0.39 | 0.87 | 0.27 |
Note: *1 means that characteristic is present (opposite to 0 - absent).
Abbreviations: AF, atrial fibrillation; AUC, under individual roc curves, CHF, congestive heart failure; CI, confidence interval; ROC, receiver operator characteristic; TIA, transient ischemic attack.